Skip to main content
    E

    Editas Medicine Inc (EDIT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.87
    -0.30 (-13.82%)

    Market Cap: $334.92M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Editas Medicine Inc (EDIT) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Editas Medicine (EDIT) is confirmed to report earnings on Mar 8, 2027, after the close. In the quarter ended Sep 30, 2026, Editas Medicine reported EPS of -$0.15, above the -$0.21 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    56%(22/39)
    Avg Surprise
    +4.78%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 8, 2027 after closePeriod ending Dec 31, 2026
    EPS Consensus-$0.19
    Range-$0.27 - -$0.08
    14 analysts
    Revenue Consensus
    $6.76M
    Range$980.00K - $21.00M
    14 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.20
    Range-$0.20 - -$0.20
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.27+25.9%
    60d ago-$0.30+33.3%
    30d ago-$0.30+33.3%
    7d ago-$0.30+33.3%
    Current-$0.20
    Revenue Consensus
    $3.13M
    Range$500.00K - $6.41M
    3 analysts

    Next Report

    EDIT has a confirmed report date of Mar 8, 2027, after the close.

    EDIT Earnings Call

    The latest EDIT earnings call transcript on file is labeled 2024Q2.

    Read the 2024Q2 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, EDIT beat 22, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $10.37M, up 37.5% from $7.54M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.15-$0.21-$0.25 - -$0.19+28.57%BeatN/A76 up, 0 downNov 9, 2026$10.37M
    Jun 30, 2026-$0.15-$0.30-$0.32 - -$0.24+50.00%BeatN/A71 up, 1 downAug 5, 2026$11.89M
    Mar 31, 2026-$0.26-$0.24-$0.30 - -$0.16-8.33%MissN/A32 up, 0 downMay 5, 2026N/A
    Dec 31, 2025-$0.06-$0.23-$0.34 - $0.08+73.94%BeatN/A61 up, 1 downMar 9, 2026$29.40M
    Sep 30, 2025-$0.28-$0.38-$0.62 - -$0.29+26.32%BeatN/A62 up, 2 downNov 10, 2025$7.54M
    Jun 30, 2025-$0.32-$0.38-$0.46 - -$0.29+15.79%BeatN/A114 up, 2 downAug 12, 2025$3.58M
    Mar 31, 2025-$0.92-$0.59-$0.84 - -$0.41-55.93%MissN/A102 up, 4 downMay 12, 2025N/A
    Dec 31, 2024-$0.55-$0.33-$0.87 - $0.10-67.38%MissN/A135 up, 2 downMar 5, 2025N/A
    Sep 30, 2024-$0.75-$0.77-$0.96 - -$0.13+2.60%BeatN/A181 up, 0 downNov 4, 2024N/A
    Jun 30, 2024-$0.82-$0.71-$0.84 - -$0.46-15.49%MissN/A170 up, 0 downAug 7, 2024N/A
    Mar 31, 2024-$0.76-$0.64-$1.09 - -$0.44-18.75%MissN/A150 up, 0 downMay 8, 2024$1.14M
    Dec 31, 2023-$0.23-$0.54-$0.75 - $0.21+57.41%BeatN/A151 up, 0 downFeb 28, 2024$60.05M
    Sep 30, 2023-$0.55-$0.58-$0.83 - -$0.45+5.17%BeatN/A161 up, 0 downNov 3, 2023$5.34M
    Jun 30, 2023-$0.56-$0.77-$0.93 - -$0.52+27.27%BeatN/A160 up, 0 downAug 2, 2023$2.89M
    Mar 31, 2023-$0.71-$0.78-$0.96 - -$0.51+8.97%BeatN/A171 up, 0 downMay 5, 2023$9.85M
    Dec 31, 2022-$0.88-$0.81-$1.00 - -$0.61-8.64%MissN/A170 up, 0 downFeb 22, 2023$13.35M
    Sep 30, 2022-$0.81-$0.85-$1.01 - -$0.72+4.71%BeatN/A160 up, 0 downNov 2, 2022N/A
    Jun 30, 2022-$0.78-$0.80-$0.93 - -$0.72+2.50%BeatN/A140 up, 0 downAug 3, 2022$6.36M
    Mar 31, 2022-$0.74-$0.79-$0.91 - -$0.69+6.33%BeatN/A131 up, 0 downMay 4, 2022N/A
    Dec 31, 2021-$0.61-$0.72-$0.91 - -$0.58+15.28%BeatN/A140 up, 0 downFeb 24, 2022N/A
    Sep 30, 2021-$0.57-$0.81-$0.93 - -$0.70+29.63%Beat-575.0%14N/ANov 8, 2021$6.20M
    Jun 30, 2021-$0.81-$0.81-$0.94 - -$0.690.00%In lineN/A11N/AAug 4, 2021$379000
    Mar 31, 2021-$0.86-$0.71-$0.92 - -$0.61-21.13%MissN/A11N/AMay 5, 2021$6.50M
    Dec 31, 2020-$1.00-$0.74-$0.84 - -$0.67-35.14%MissN/A8N/AFeb 25, 2021$27.89M
    Sep 30, 2020$0.12-$0.63-$0.81 - -$0.47+119.05%BeatN/A9N/ANov 5, 2020$62.84M
    Jun 30, 2020-$0.43-$0.82-$0.96 - -$0.62+47.56%BeatN/A9N/AAug 6, 2020N/A
    Mar 31, 2020-$0.69-$0.79-$0.93 - -$0.64+12.66%BeatN/A8N/AMay 7, 2020N/A
    Dec 31, 2019-$0.74$0.06N/AN/AN/AN/AN/AN/AFeb 26, 2020$12.28M
    Sep 30, 2019-$0.66-$0.73N/A+9.59%BeatN/AN/AN/ANov 12, 2019$3.85M
    Jun 30, 2019-$0.69-$0.62N/A-11.29%MissN/AN/AN/AAug 6, 2019$2.33M
    Mar 31, 2019-$0.60-$0.64N/A+6.25%BeatN/AN/AN/AMay 7, 2019$2.07M
    Dec 31, 2018-$0.52-$0.32N/A-62.50%MissN/AN/AN/AFeb 28, 2019N/A
    Sep 30, 2018-$0.32-$0.81-$0.91 - -$0.38+60.49%BeatN/A8N/ANov 7, 2018$14.52M
    Jun 30, 2018-$0.82-$0.66-$0.74 - -$0.44-24.24%MissN/A7N/AAug 6, 2018$7.37M
    Mar 31, 2018-$0.67-$0.80-$0.92 - -$0.72+16.25%BeatN/A7N/AMay 3, 2018$3.93M
    Dec 31, 2017-$0.84-$0.78-$1.36 - -$0.52-7.69%MissN/A7N/AMar 6, 2018$3.67M
    Sep 30, 2017-$0.64-$0.63-$0.75 - -$0.48-1.59%MissN/A6N/ANov 7, 2017$6.28M
    Jun 30, 2017-$0.65-$0.57-$1.01 - -$0.52-14.04%MissN/A5N/AAug 9, 2017$3.10M
    Mar 31, 2017-$0.85-$0.77-$0.77 - -$0.33-10.39%MissN/A4N/AMay 15, 2017$682000
    Dec 31, 2016-$1.10-$0.62N/A-77.42%MissN/AN/AN/AMar 7, 2017$898000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.58, after -$2.88 the year before. It was -$3.03 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.58N/A
    Dec 31, 2024-$2.88N/A
    Dec 31, 2023-$2.05N/A
    Dec 31, 2022-$3.21N/A
    Dec 31, 2021-$2.85N/A
    Dec 31, 2020-$2.00N/A
    Dec 31, 2019-$2.69N/A
    Dec 31, 2018-$2.33N/A
    Dec 31, 2017-$2.98N/A
    Dec 31, 2016-$3.03N/A

    Earnings Calls

    The only earnings call listed below, 2024Q2 for the period ended Jun 30, 2024, runs about 7,900 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q2Jun 30, 20247,88318

    2024Q2 Earnings Call

    Opening remarks

    Cristi Barnett Corporate Communications and Investor Relations Thank you, Britney. Good morning, everyone and welcome to our second quarter 2024 conference call. Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today’s call will be available in the Investors section of our website approximately two hours after its completion. After our prepared remarks, we will open the call for Q&A. As a reminder, various remarks that we make during this call about the company’s future expectations, plans and prospects constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including those discussed in the Risk Factors section of our most recent Annual Report on Form 10-K, which is on file with the SEC, as updated by our subsequent filings. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change. Now, I will turn the call over to our CEO, Gilmore O’Neill.

    Gilmore O’Neill CEO Thanks, Cristi and good morning everyone. Thank you for joining us today on Editas’ second quarter 2024 earnings call. With me today are four members of the Editas executive team, our Chief Medical Officer, Baisong Mei; our Chief Financial Officer, Erick Lucera; our Chief Scientific Officer, Linda Burkly; and our Chief Commercial and Strategy Officer, Caren Deardorf. Because it is summertime, we are going to keep today’s prepared remarks brief and leave more time to take your questions. Let me start by saying that we are pleased with Editas’ momentum and progress in the second quarter of 2024 as we pursue Editas’ goal to deliver life-changing medicines to patients with untreatable or undertreated genetic diseases and to position Editas as a leader in in-vivo programmable gene editing. Three pillars underpin our strategy. The first of those pillars is to drive reni-cel, a gene edited cell therapy for hemoglobinopathies, formerly known as EDIT-301, toward BLA and commercialization. Second, to build a differentiated in-vivo editing pipeline and third, to increase business development activities with a particular focus on monetizing our very strong IP. At the start of 2024, we announced the following 2024 objectives. For reni-cel, we will provide a clinical update from the RUBY trial for severe sickle cell disease and the EdiTHAL trial for transfusion-dependent beta thalassemia in mid-2024 and by year-end 2024.

    Frequently Asked Questions About EDIT

    When is Editas Medicine's next earnings date?

    Editas Medicine's next earnings report is confirmed for Mar 8, 2027, after the close.

    Did EDIT beat earnings estimates last quarter?

    Yes. Editas Medicine reported EPS of -$0.15 for the quarter ended Sep 30, 2026, above the -$0.21 estimate, a 28.57% surprise.

    What EPS do analysts expect from EDIT next quarter?

    The consensus EPS estimate for Editas Medicine for the quarter ending Dec 31, 2026 is -$0.19 from 14 analysts, with estimates from -$0.27 to -$0.08.

    How often does EDIT beat earnings estimates?

    Editas Medicine beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +7.87%.

    Does EDIT report before or after the market opens?

    Editas Medicine is confirmed to report on Mar 8, 2027, after the market closes.